Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":139324614,"tweetId":"139324614","gmtCreate":1621594826338,"gmtModify":1634187804718,"author":{"id":3581577540266884,"idStr":"3581577540266884","authorId":3581577540266884,"authorIdStr":"3581577540266884","name":"JohnsonYeo","avatar":"https://static.tigerbbs.com/7139a0ce522ecb24fe97876b7ccfa905","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like</body></html>","htmlText":"<html><head></head><body>Like</body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/139324614","repostId":1196025603,"repostType":4,"repost":{"id":"1196025603","kind":"news","pubTimestamp":1621593525,"share":"https://www.laohu8.com/m/news/1196025603?lang=&edition=full","pubTime":"2021-05-21 18:38","market":"us","language":"en","title":"Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role","url":"https://stock-news.laohu8.com/highlight/detail?id=1196025603","media":"InvestorPlace","summary":"OCGN stock faces some tough vaccine math in its home country.\n\nWhileOcugen(NASDAQ:OCGN) stock is up ","content":"<blockquote>\n OCGN stock faces some tough vaccine math in its home country.\n</blockquote>\nWhileOcugen(NASDAQ:OCGN) stock is up over 200% this year, ithasn’tbeen a case of slow and steady growth. On two separate occasions, the shares have been much higher. Yet when I wrote about OCGN stocka month ago, the stock was about 40% below its current price.\n<img src=\"https://static.tigerbbs.com/160226899c7a4d832ba23044479cfb70\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock\nVolatility like that&nbsp;merits some explanation. The first time OCGN stock popped, in mid-February waslikely dueto the meme stock craze. But when the stock spiked in April, it was due to a more fundamental reason.Ocugenhad become a recognized player in the Covid-19 vaccine rollout.\nThat would be more intriguing ifOcugenwas developing its own vaccine. Not that it would make it any less of a long shot, but right now the company is serving the role of a middleman. And it could wind up getting cut out entirely.\nAmericaDoesn’t&nbsp;NeedCovaxin\nAs I noted last month,Ocugenis in a partnershipwith India’sBharat Biotechregarding&nbsp;the latter company’s Covid-19 vaccine,Covaxin. Specifically,Ocugen&nbsp;will get 45% of the profits from the sale ofCovaxinin the United States.\nThe concern I had then is the same concern I have now. The U.S. does notrequire&nbsp;another Covid-19 vaccine. And, althoughCovaxinhas received an emergency use authorization in India, it continues toundergo Phase 3 trials.\nUnder terms of the agreement,Ocugen&nbsp;willbe responsible for&nbsp;the vaccine’s clinical development, regulatory approval (which includes its EUA) and commercialization in the U.S.\nAnd as myInvestorPlace&nbsp;colleague Larry Ramer points out,&nbsp;thatapproval appears unlikely.&nbsp;Ramer recentlyobserved&nbsp;that the FDA’s written protocols state that to grant an EUA it “should carry out visits to the sites at which Phase 3 trials are being carried out.”\nThat would mean the FDA would have to go to India which is currently under a travel ban by the U.S.\nNot Part of the Arsenal\nOne of the recent bullish arguments for OCGN stock is that the company willbenefit&nbsp;fromIndia’s pause on exportingCovaxin. India will not export the vaccine until at least October to stem the ongoing surge in that country. The rationale is thatOcugenwill benefit as more vaccines will need to be created and exported.\nBut again,I’m&nbsp;skeptical. First, asI’vepointed out, the United States is not a nation that needs to import vaccines. In fact, President Biden is pledging that the U.S. will be anarsenal for global distribution&nbsp;of Covid-19 vaccines. OnMay 17,2021&nbsp;the president announced that the U.S. would share anadditional&nbsp;20 million doses of the vaccine. This was in addition to the 60 million doses that have already been exported.\nThis brings me to a second point. Currently,Covaxinis not part of that arsenal. And even if it were,it’sunclear how exporting Covaxin would work withOcugen’s&nbsp;agreement in which the company receives compensation for sales ofCovaxinwithin the United States(emphasis mine).\nThere Are Better Options Than OCGN Stock\nOcugen&nbsp;specializes in treating rare eye diseases. Theydon’tcurrently have a product in market. But one of their candidates,INO-4000, is beginning the clinical trial stage.&nbsp;The partnership withBahrat&nbsp;Biotech may be successful in raising some non-dilutive revenue. But for reasonsI’venoted in this article, that should not be seen as a given.\nThere are other small-cap biotech companies that may have better odds of bringing anadditionalCovid-19 vaccine to market. I would suggest&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO) or&nbsp;iBio(NYSEAMERICAN:IBIO). These companies also face long odds.Howeverboth areat least manufacturing their own vaccine. And both companies are bringing something innovative to the table.\nI’massuming Ocugen’s motives for trying toassistin the Covid-19 vaccine race are pure. I imagine all biotech companies want to alleviate suffering and needless death from this virus. But the company is facing longer odds to achieve that goal thanI believe short-term tradersare considering.\nOn the date of publication, ChrisMarkochdid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Faces Long Odds Before Gaining From Its Covid-19 Support Role\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-21 18:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/ocgn-stock-faces-long-odds-in-covid-support-role/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nOCGN stock faces some tough vaccine math in its home country.\n\nWhileOcugen(NASDAQ:OCGN) stock is up over 200% this year, ithasn’tbeen a case of slow and steady growth. On two separate occasions, the ...\n\n<a href=\"https://investorplace.com/2021/05/ocgn-stock-faces-long-odds-in-covid-support-role/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/05/ocgn-stock-faces-long-odds-in-covid-support-role/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196025603","content_text":"OCGN stock faces some tough vaccine math in its home country.\n\nWhileOcugen(NASDAQ:OCGN) stock is up over 200% this year, ithasn’tbeen a case of slow and steady growth. On two separate occasions, the shares have been much higher. Yet when I wrote about OCGN stocka month ago, the stock was about 40% below its current price.\nSource: Shutterstock\nVolatility like that merits some explanation. The first time OCGN stock popped, in mid-February waslikely dueto the meme stock craze. But when the stock spiked in April, it was due to a more fundamental reason.Ocugenhad become a recognized player in the Covid-19 vaccine rollout.\nThat would be more intriguing ifOcugenwas developing its own vaccine. Not that it would make it any less of a long shot, but right now the company is serving the role of a middleman. And it could wind up getting cut out entirely.\nAmericaDoesn’t NeedCovaxin\nAs I noted last month,Ocugenis in a partnershipwith India’sBharat Biotechregarding the latter company’s Covid-19 vaccine,Covaxin. Specifically,Ocugen will get 45% of the profits from the sale ofCovaxinin the United States.\nThe concern I had then is the same concern I have now. The U.S. does notrequire another Covid-19 vaccine. And, althoughCovaxinhas received an emergency use authorization in India, it continues toundergo Phase 3 trials.\nUnder terms of the agreement,Ocugen willbe responsible for the vaccine’s clinical development, regulatory approval (which includes its EUA) and commercialization in the U.S.\nAnd as myInvestorPlace colleague Larry Ramer points out, thatapproval appears unlikely. Ramer recentlyobserved that the FDA’s written protocols state that to grant an EUA it “should carry out visits to the sites at which Phase 3 trials are being carried out.”\nThat would mean the FDA would have to go to India which is currently under a travel ban by the U.S.\nNot Part of the Arsenal\nOne of the recent bullish arguments for OCGN stock is that the company willbenefit fromIndia’s pause on exportingCovaxin. India will not export the vaccine until at least October to stem the ongoing surge in that country. The rationale is thatOcugenwill benefit as more vaccines will need to be created and exported.\nBut again,I’m skeptical. First, asI’vepointed out, the United States is not a nation that needs to import vaccines. In fact, President Biden is pledging that the U.S. will be anarsenal for global distribution of Covid-19 vaccines. OnMay 17,2021 the president announced that the U.S. would share anadditional 20 million doses of the vaccine. This was in addition to the 60 million doses that have already been exported.\nThis brings me to a second point. Currently,Covaxinis not part of that arsenal. And even if it were,it’sunclear how exporting Covaxin would work withOcugen’s agreement in which the company receives compensation for sales ofCovaxinwithin the United States(emphasis mine).\nThere Are Better Options Than OCGN Stock\nOcugen specializes in treating rare eye diseases. Theydon’tcurrently have a product in market. But one of their candidates,INO-4000, is beginning the clinical trial stage. The partnership withBahrat Biotech may be successful in raising some non-dilutive revenue. But for reasonsI’venoted in this article, that should not be seen as a given.\nThere are other small-cap biotech companies that may have better odds of bringing anadditionalCovid-19 vaccine to market. I would suggest Inovio Pharmaceuticals (NASDAQ:INO) or iBio(NYSEAMERICAN:IBIO). These companies also face long odds.Howeverboth areat least manufacturing their own vaccine. And both companies are bringing something innovative to the table.\nI’massuming Ocugen’s motives for trying toassistin the Covid-19 vaccine race are pure. I imagine all biotech companies want to alleviate suffering and needless death from this virus. But the company is facing longer odds to achieve that goal thanI believe short-term tradersare considering.\nOn the date of publication, ChrisMarkochdid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":469,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/139324614"}